Figure 2 | Neuropsychopharmacology

Figure 2

From: Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence

Figure 2

Plasma ACTH levels determined in subjects at predetermined time points from samples obtained over a range of 30 min before to 480 min after administration of 10 mg/kg Opra Kappa (or the corresponding time on baseline day 1). (a) Time course of plasma ACTH levels in combined male and female healthy volunteers (n=16) on day 1 of study (baseline day), day 2 of study (day 1 of Opra Kappa administration), and day 5 of study (day 4 of Opra Kappa administration). (b) Time course of plasma ACTH levels in combined male and female EACD subjects (n=14) on day 1 of study (baseline day), day 2 of study (day 1 of Opra Kappa administration), and day 5 of study (day 4 of Opra Kappa administration). (c) Area under the curve, from 0 to 480 min with respect to OpRA Kappa administration, for HV subjects (n=16) and EACD subjects (n=13).

PowerPoint slide

Back to article page